Super PACs With Alleged AIPAC Ties Intervene in Oregon Dem Primary
The two PACs have spent nearly $1 million on the race in recent weeks.
David Moore
Page 15
Hochul Raised Big Bucks From Real Estate Moguls Before Housing Deal
A Sludge analysis found that New York Gov. Kathy Hochul has received at least $1.5 million from real estate industry donors since the start of 2023.
AIPAC Makes Record High Contributions as Its Super PAC Fights Progressives
New disclosures covering March show that AIPAC's PAC made $4.1 million in contributions to federal candidates, while its super PAC raised another $1.8 million ahead of a spending wave against progressive candidates.
AIPAC-Tied DMFI Raises More From Private Equity Execs
Democratic Majority for Israel (DMFI) super PAC brought in most of the funding in its new FEC report from a handful of private equity executives and investment industry donors.
Billionaires Fund the GOP’s Senate Takeover Attempt, With Tax Cuts at Stake
In Montana and other Senate battlegrounds, super PACs backing Republicans have been heavily funded by finance billionaires Stephen Schwarzman, Ken Griffin, and others.
Trump Sees $4 Billion Windfall From Deal With Megadonor-Tied Firm
Billionaire Republican megadonor Jeff Yass' trading firm was a large investor in the acquisition company that sent Trump's paper fortune soaring.
House Dems Donate to Centrist Group That Undermines Their Agenda
House Democratic leadership groups have given more than a million dollars to the PhRMA-funded Center Forward, which has worked to undermine the Biden administration on drug pricing reforms and more.
‘Reject AIPAC’ Coalition Launches to Challenge the Pro-Israel Group’s Political Influence
A new coalition of progressive groups is calling on candidates to reject AIPAC donations and spending in Democratic primaries.
Who’s Funding AIPAC’s Political Spending Barrage?
Here are the tech industry founders, Republican megadonors and others funding AIPAC and its closely-tied allies this election cycle.
PhRMA Funnels Millions to Groups Fighting Drug Pricing Reforms
The pharma lobby gave more than $16 million in 2022 to advocacy groups, many of them ostensibly “grassroots,” that are battling the Medicare drug price negotiations now underway.